Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT06057402

RecruitingPhase 4

Sponsor: Pfizer

Conditions: Multiple Myeloma

Interventions: Elranatamab

Countries: United States, Australia, Canada, China, Japan, Spain, Taiwan

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Participants must agree to follow the reproductive criteria as outlined in the protocol
* Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

Exclusion Criteria:

* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
* Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.
Locations (33)
  • Irvine, California, United States
  • Orange, California, United States
  • Orange, California, United States
  • Fort Collins, Colorado, United States
  • Fort Collins, Colorado, United States
  • Greeley, Colorado, United States
  • Longmont, Colorado, United States
  • Longmont, Colorado, United States
  • Loveland, Colorado, United States
  • Coral Gables, Florida, United States
  • Deerfield Beach, Florida, United States
  • Miami, Florida, United States
  • Miami, Florida, United States
  • Miami, Florida, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Austin, Texas, United States
  • Melbourne, Victoria, Australia
  • Richmond, Victoria, Australia
  • Richmond, Victoria, Australia
  • Calgary, Alberta, Canada
  • Edmonton, Alberta, Canada
  • Montreal, Quebec, Canada
  • Beijing, Beijing Municipality, China
  • Guangzhou, Guangdong, China
  • Jinan, Shandong, China
  • Hangzhou, Zhejiang, China
  • Shibuya-ku, Tokyo, Japan
  • Kyoto, Japan
  • Pamplona, Navarre, Spain
  • + 3 more on CT.gov